Can growth hormone therapy cause diabetes?

Monson, JP; Ba, Bengtsson; Abs, R.; Feldt‐Rasmussen, Ulla; Wüster, Christian

doi:10.1016/s0140-6736(05)73137-8

Cited by 26 publications

(17 citation statements)

References 2 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Initially, there was concern that GH replacement would increase this prevalence further by increasing insulin resistance and hence diabetes rates. Although in the short term fasting plasma glucose may rise on commencing GH replacement (53), improvements in LBM and WHR offset these changes and in the longterm there is no rise in HbA1c (51,52) or plasma glucose (54). After 1 year of GH replacement, normalisation of insulin sensitivity and plasma glucose diurnal variation are seen (55).…”

Section: Other Cardiovascular Risk Factorsmentioning

confidence: 99%

Adult GH deficiency throughout lifetime

Thomas

Monson

2009

European Journal of Endocrinology

View full text Add to dashboard Cite

It is now accepted that adults with severe GH deficiency (GHD) demonstrate impaired physical and psychological well-being and may benefit from replacement with recombinant human GH. Postmarketing surveillance surveys, such as the Pfizer International Metabolic Database (KIMS), were initially set-up to provide safety data on long-term treatment but have the added benefit of providing ongoing observational data on the effect of GH replacement on body composition, lipid and glucose status, hypertension, bone density and quality of life. These data demonstrate that although GHD has clinical impact at all ages, the individual consequences of this condition may take on greater significance at different stages in life. At all ages, accurate, safe diagnosis and appropriate GH dosing are necessary to provide the individual with the best possible outcome.

show abstract

Section: Other Cardiovascular Risk Factorsmentioning

confidence: 99%

Adult GH deficiency throughout lifetime

Thomas

Monson

2009

European Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…In one study, while prevalence was unaffected by GH replacement therapy, baseline metabolic syndrome status or obesity were strong predictors of the metabolic syndrome after 3 years of GH treatment [Attanasio et al 2010]. Conversely, GH replacement reduces abdominal fat mass and may therefore improve insulin resistance and glucose homeostasis in adult patients with GHD [Monson et al 2000]. This has been documented in some studies [Svensson et al 2002] but not in others [Arwert et al 2005].…”

Section: Data Collection and Analysismentioning

confidence: 97%

Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope^® for the treatment of adult patients with growth hormone deficiency

Beck‐Peccoz

Minuto

Leal‐Cerro

et al. 2012

Therapeutic Advances in Endocrinology

View full text Add to dashboard Cite

Abstract:Objective: To describe the rationale and design of PATRO Adults, a postmarketing surveillance study of the long-term efficacy and safety of somatropin (Omnitrope ® ) for the treatment of adult patients with growth hormone deficiency (GHD). Methods: PATRO Adults is an observational, multicentre, open, longitudinal, noninterventional study being conducted in hospitals and specialized endocrinology clinics across several European countries. The primary objective is to assess the safety and efficacy of Omnitrope ® in adults treated in routine clinical practice. Eligible patients are male or female adults who are receiving treatment with Omnitrope ® and who have provided informed consent. Patients who have been treated with another human growth hormone (hGH) product before starting Omnitrope ® therapy will also be eligible for inclusion. Efficacy assessments will be based on the analysis of the following: insulin-like growth factor-1 levels within age-and gender-adjusted normal ranges; anthropometric measures (weight, waist circumference, total fat mass, lean body mass, total body water); bone mineral density; lipids; effects on cardiovascular risk factors such as glucose metabolism, blood pressure and inflammatory markers (e.g. C-reactive protein); and quality of life. All adverse events will be monitored and recorded. Particular emphasis will be placed on long-term safety, the recording of malignancies, the occurrence and clinical impact of antirecombinant hGH antibodies, the incidence, severity and duration of hyperglycaemia, and the development of diabetes during treatment with Omnitrope ® .

show abstract

“…Auch gibt es keine Hinweise dafür, dass eine Wachstumshormonsubstitution das Risiko für das Auftreten eines Diabetes mellitus steigert [76].…”

Section: Therapeutische Sicherheitunclassified

Wachstumshormontherapie im Erwachsenenalter: Eine aktuelle Übersicht

Kann

2011

Wien Klin Wochenschr

View full text Add to dashboard Cite

Growth hormone deficiency (GHD) can frequently be expected in hypopituitarism of adult patients. If GHD is proven by dynamic testing of the somatotrophic axis, growth hormone substitution is useful for improving quality of life, body composition, bone and lipid metabolism, and myocardial function according to the criteria of evidence-based medicine and is admitted by most national health authorities. There are no other reasonable indications for growth hormone treatment in adulthood.

show abstract

Can growth hormone therapy cause diabetes?

Cited by 26 publications

References 2 publications

Adult GH deficiency throughout lifetime

Adult GH deficiency throughout lifetime

Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope^® for the treatment of adult patients with growth hormone deficiency

Wachstumshormontherapie im Erwachsenenalter: Eine aktuelle Übersicht

Contact Info

Product

Resources

About

Can growth hormone therapy cause diabetes?

Cited by 26 publications

References 2 publications

Adult GH deficiency throughout lifetime

Adult GH deficiency throughout lifetime

Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope® for the treatment of adult patients with growth hormone deficiency

Wachstumshormontherapie im Erwachsenenalter: Eine aktuelle Übersicht

Contact Info

Product

Resources

About

Rationale and design of PATRO Adults, a multicentre, noninterventional study of the long-term efficacy and safety of Omnitrope^® for the treatment of adult patients with growth hormone deficiency